Moffitt Imaging Biomarker VAlidation Center

 描述（由申请人提供）：我们建议建立Moffitt成像生物标志物验证中心（MIBVAC），通过利用我们强大的专家团队、资源、计划的成像生物标志物验证研究以及分析和网络协作结构，专注于早期癌症检测和准确风险评估的成像生物标志物验证。在以前的研究中，我们已经证明，从乳房图像的各种测量量化乳腺癌的风险。大型合作性国家肺筛查试验（NLST）也显示，与常规X线摄影筛查相比，低剂量CT筛查的个体生存率显著提高。此外，我们最近已经表明，CT图像分析（放射组学）可以提高该数据集的分类。然而，由于难以获得准确和可重复的测量结果以及当前成像的高假阳性率，癌症成像生物标志物尚未常规纳入临床风险评估。如果这些成像生物标志物可以在个体水平上精确定制，它们对早期癌症检测和干预的影响将显着改善。MIBVAC计划通过严格评估和验证这些成像生物标志物以快速转化为临床和实际应用来实现这一具有挑战性但相当可实现的目标。我们有四个具体目标：（目的1）使用我们现有的和新的乳腺图像病例对照数据集为EDRN建立乳腺成像资源，并基于新建立的数字乳腺断层合成（TS）图像病例对照数据集评估和验证乳腺成像生物标志物，（目的2）首先基于NLST低剂量CT（LDCT）队列评估和验证用于早期检测癌症的肺部成像生物标志物，然后用新的-建立更高分辨率LDCT的病例对照队列，（目标3）对EDRN合作伙伴和其他恶性肿瘤的成像生物标志物进行验证研究，（目标4）通过分析优化和验证成像生物标志物，用于乳腺癌、肺癌和其他癌症的早期检测，并构建用于EDRN合作和共享的MIBVAC成像数据和标本资源。

 DESCRIPTION (provided by applicant): We propose to establish the Moffitt Imaging Biomarker Validation Center (MIBVAC) focused on imaging biomarker validations for early cancer detection and accurate risk assessments by leveraging our team of strong experts, resources, planned imaging biomarker validation studies, and analysis and network collaboration structures. In previous studies we have demonstrated that various measurements from breast images quantify breast cancer risk. The large cooperative National Lung Screening Trial (NLST) also showed a significant survival improvement for individuals screened by low dose CT compared to those screened with conventional radiography. Additionally, we have recently shown that CT image analysis (radiomics) can improve classification in this data set. However, due to difficulties in obtaining accurate and reproducible measurements and high false-positive rates of current imaging, cancer imaging biomarkers have not been routinely incorporated into clinical risk assessment. If these imaging biomarkers can be accurately tailored at the individual level, their impact will be significantly improved for early cancer detection and intervention. MIBVAC plans to achieve this challenging yet quite achievable goal by rigorously evaluating and validating these imaging biomarkers for rapid translation into clinical and practical applications. We have four specific aims: (Aim 1) Establish breast imaging resources for EDRN both with our existing and new case-control datasets of breast images and to evaluate and validate breast imaging biomarkers based on newly-established case-control dataset of digital breast tomosynthesis (TS) images, (Aim 2) Evaluate and validate lung imaging biomarkers for early detection of cancer first based on NLST low-dose CT (LDCT) cohorts and then expanding with a newly-established case-control cohort of higher resolution LDCT, (Aim 3) Conduct validation studies with imaging biomarkers for EDRN partners and others for other malignancies, and (Aim 4) Refine and validate imaging biomarkers analytically for early detection of breast, lung, and other cancers and to construct MIBVAC imaging data and specimen resources for EDRN collaborations and sharing.